- Home
- TNGX vs GRRRW Comparison
TNGX vs GRRRW Comparison
Compare TNGX & GRRRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- GRRRW
- Stock Information
- Founded
- TNGX 2014
- GRRRW N/A
- Country
- TNGX United States
- GRRRW United Kingdom
- Employees
- TNGX N/A
- GRRRW N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- GRRRW Computer Software: Prepackaged Software
- Sector
- TNGX Health Care
- GRRRW Technology
- Exchange
- TNGX Nasdaq
- GRRRW Nasdaq
- Market Cap
- TNGX 351.2M
- GRRRW N/A
- IPO Year
- TNGX N/A
- GRRRW N/A
- Fundamental
- Price
- TNGX $5.02
- GRRRW $0.76
- Analyst Decision
- TNGX Strong Buy
- GRRRW
- Analyst Count
- TNGX 6
- GRRRW 0
- Target Price
- TNGX $12.20
- GRRRW N/A
- AVG Volume (30 Days)
- TNGX 4.0M
- GRRRW 336.7K
- Earning Date
- TNGX 08-06-2025
- GRRRW 04-04-2025
- Dividend Yield
- TNGX N/A
- GRRRW N/A
- EPS Growth
- TNGX N/A
- GRRRW N/A
- EPS
- TNGX N/A
- GRRRW 2.28
- Revenue
- TNGX $40,990,000.00
- GRRRW $78,940,347.00
- Revenue This Year
- TNGX N/A
- GRRRW N/A
- Revenue Next Year
- TNGX N/A
- GRRRW N/A
- P/E Ratio
- TNGX N/A
- GRRRW $25.04
- Revenue Growth
- TNGX 10.09
- GRRRW 424.97
- 52 Week Low
- TNGX $1.03
- GRRRW $1.06
- 52 Week High
- TNGX $12.02
- GRRRW $1.54
- Technical
- Relative Strength Index (RSI)
- TNGX 69.44
- GRRRW N/A
- Support Level
- TNGX $4.70
- GRRRW N/A
- Resistance Level
- TNGX $5.63
- GRRRW N/A
- Average True Range (ATR)
- TNGX 0.60
- GRRRW 0.00
- MACD
- TNGX -0.01
- GRRRW 0.00
- Stochastic Oscillator
- TNGX 65.38
- GRRRW 0.00
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.